RxDoctor Payments Data

Ellie Fong, PA

Physician Assistant · Seal Beach, CANPI 1831251990

Payments from drug & device makers

$5,252in general payments, 2019–2025

Across 212 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Corcept Therapeutics$562
  • Abbott$559
  • Dexcom, Inc.$396
  • Tandem Diabetes Care, Inc.$387
  • Insulet Corporation$363
  • plus $2K from 15 others

What the payments were for

  • Speaking & faculty fees$1753%
  • Travel & lodging$80%
  • Food & beverage$5,05896%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,252 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$32,475
Medicare patients
96
Services billed
426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide142$270,108
TrulicityDulaglutide60$103,651
MounjaroTirzepatide59$100,078
JardianceEmpagliflozin63$84,591
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/723$48,363
Synjardy XrEmpagliflozin/Metformin Hcl24$41,007
RybelsusSemaglutide18$25,335
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$22,390
FarxigaDapagliflozin Propanediol13$20,484
JanuviaSitagliptin Phosphate14$20,245
Tresiba Flextouch U-200Insulin Degludec15$16,836
Fiasp FlextouchInsulin Aspart (Niacinamide)19$15,952
Nano 2nd Gen Pen NeedlePen Needle, Diabetic89$12,906
HumalogInsulin Lispro27$12,016
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$10,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$302$295,442160 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$1,466$215,745146 claims
Boehringer IngelheimJardiance, Synjardy Xr$244$125,59887 claims
MerckJanuvia$33$20,24514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Seal Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →